1.6.2017 13:02 | Nasdaq OMX
Merus to Present at the Jefferies 2017 Global Healthcare Conference
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl . An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
+1 973 361 1546
+1 646 368 8014
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
InSphero AG29.6.2017 14:01 | pressemeddelelse
Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury
IC Potash Corp.29.6.2017 13:31 | pressemeddelelse
IC Potash announces closing of Private Placement Financing and results of 2017 annual shareholders' meeting
Standard Lithium Ltd.29.6.2017 11:32 | pressemeddelelse
Standard Lithium Ltd. : Standard Lithium Commences CSAMT/MT Geophysical Survey at Bristol Lake, Mojave Project, California
Minerva Neurosciences, Inc.29.6.2017 00:49 | pressemeddelelse
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
Yandy.com28.6.2017 20:20 | pressemeddelelse
Yandy.com Celebrates Baywatch Movie With Inspired-By Swim Collection
Nasdaq28.6.2017 16:07 | pressemeddelelse
Nasdaq's Directors Desk® and Boardvantage® to Introduce Board Assessments and Compliance Questionnaires
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum